Minnelide 明奈利德|cas:1254702-87-8|西域试剂

Minnelide 明奈利德,99.59%

产品编号：Bellancom-124584| CAS NO：1254702-87-8| 分子式：C₂₁H₂₅Na₂O₁₀P| 分子量：514.37

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-124584	￥2500.00	杭州北京（现货）
Bellancom-124584	￥4500.00	杭州北京（现货）
Bellancom-124584	￥8500.00	杭州北京（现货）
Bellancom-124584	￥13500.00	杭州北京（现货）
Bellancom-124584	￥19500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Minnelide 明奈利德

产品介绍

Minnelide 是雷公藤内酯的衍生物，在许多肿瘤类型 (特别是在胰腺癌) 中显示出抗肿瘤 (antitumor) 活性。 Minnelide 可导致凋亡 (apoptosis)。

生物活性

Minnelide is a prodrug of triptolide that shows potent antitumor activity in a number of tumor types, particularly in pancreatic cancer. Minnelide promotes apoptosis.

体外研究

Minnelide (0-200 nM; 48 hours) shows significantly decreased cell viability in pancreatic cancer cell lines after treatment in the presence, but not in the absence, of phosphatase.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Pancreatic cancer cell line: S2-013, MIA PaCa-2, S2-VP10, and Panc-1 cells
Concentration:	0.100 nM, 200 nM
Incubation Time:	48 hours
Result:	Decreased cell viability of in vitro.

体内研究
(In Vivo)

Minnelide (injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily) leads to a marked decrease in tumor weight and volume at the end of treatment and increases survival in orthotopic model of pancreatic cancer with MIA PaCa-2–derived human pancreatic tumors.
Minnelide (injection intraperitoneally; 0.42 mg/kg; once daily; 28 days) prevents locoregional spread and leads to a decrease in average tumor weight in a xenograft model of pancreatic cancer with metastatic S2-013 cells.
Minnelide (injection intraperitoneally; 0.42 mg/kg, 0.21 mg/kg; once daily) causes tumor regression and tumors from Minnelide-treated animals showed fibrosis and the presence of pyknotic nuclei in human pancreatic cancer xenografts in SCID mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Orthotopic model of pancreatic cancer with MIA PaCa 2-derived human pancreatic tumors in athymic nude mice
Dosage:	0.1-0.6 mg/kg
Administration:	Injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily
Result:	Prevented pancreatic tumor growth in vivo.

Animal Model:	Xenograft model of pancreatic cancer with metastatic S2-013 cell line in athymic nude mice
Dosage:	0.42 mg/kg
Administration:	Injection intraperitoneally; 0.42 mg/kg; once daily
Result:	Prevented extensive spread from the primary site of injection.

Animal Model:	Human pancreatic cancer xenografts in SCID mice
Dosage:	0.21 mg/kg, 0.42 mg/kg
Administration:	Injection intraperitoneally; 0.42 mg/kg; once daily
Result:	Reduced tumor burden in human xenografts from patients.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Orthotopic model of pancreatic cancer with MIA PaCa 2-derived human pancreatic tumors in athymic nude mice
Dosage:	0.1-0.6 mg/kg
Administration:	Injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily
Result:	Prevented pancreatic tumor growth in vivo.

Animal Model:	Xenograft model of pancreatic cancer with metastatic S2-013 cell line in athymic nude mice
Dosage:	0.42 mg/kg
Administration:	Injection intraperitoneally; 0.42 mg/kg; once daily
Result:	Prevented extensive spread from the primary site of injection.

Animal Model:	Human pancreatic cancer xenografts in SCID mice
Dosage:	0.21 mg/kg, 0.42 mg/kg
Administration:	Injection intraperitoneally; 0.42 mg/kg; once daily
Result:	Reduced tumor burden in human xenografts from patients.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Orthotopic model of pancreatic cancer with MIA PaCa 2-derived human pancreatic tumors in athymic nude mice
Dosage:	0.1-0.6 mg/kg
Administration:	Injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily
Result:	Prevented pancreatic tumor growth in vivo.

Animal Model:	Xenograft model of pancreatic cancer with metastatic S2-013 cell line in athymic nude mice
Dosage:	0.42 mg/kg
Administration:	Injection intraperitoneally; 0.42 mg/kg; once daily
Result:	Prevented extensive spread from the primary site of injection.

Animal Model:	Human pancreatic cancer xenografts in SCID mice
Dosage:	0.21 mg/kg, 0.42 mg/kg
Administration:	Injection intraperitoneally; 0.42 mg/kg; once daily
Result:	Reduced tumor burden in human xenografts from patients.

性状

Solid

溶解性数据

In Vitro:

H₂O : 93.33 mg/mL (181.45 mM; Need ultrasonic)

DMSO : 16.67 mg/mL (32.41 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9441 mL	9.7206 mL	19.4413 mL
5 mM	0.3888 mL	1.9441 mL	3.8883 mL
10 mM	0.1944 mL	0.9721 mL	1.9441 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 1.67 mg/mL (3.25 mM); Clear solution

此方案可获得 ≥ 1.67 mg/mL (3.25 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1.67 mg/mL (3.25 mM); Clear solution

此方案可获得 ≥ 1.67 mg/mL (3.25 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 1.67 mg/mL (3.25 mM); Clear solution

此方案可获得 ≥ 1.67 mg/mL (3.25 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。